1. Home
  2. AGEN vs HIX Comparison

AGEN vs HIX Comparison

Compare AGEN & HIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$6.84

Market Cap

335.6M

Sector

Health Care

ML Signal

N/A

Logo Western Asset High Income Fund II Inc.

HIX

Western Asset High Income Fund II Inc.

N/A

Current Price

$3.50

Market Cap

351.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AGEN
HIX
Founded
1994
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
335.6M
351.3M
IPO Year
1999
1998

Fundamental Metrics

Financial Performance
Metric
AGEN
HIX
Price
$6.84
$3.50
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $26.33
N/A
AVG Volume (30 Days)
★ 856.6K
358.6K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
★ 13.14%
EPS Growth
★ 100.00
N/A
EPS
★ 0.96
N/A
Revenue
★ $42,877,086.00
N/A
Revenue This Year
$9.64
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.35
★ N/A
Revenue Growth
★ 89.95
N/A
52 Week Low
$2.71
$3.34
52 Week High
$10.19
$4.33

Technical Indicators

Market Signals
Indicator
AGEN
HIX
Relative Strength Index (RSI) 45.89 47.01
Support Level $6.66 $3.46
Resistance Level $8.64 $4.04
Average True Range (ATR) 0.46 0.05
MACD 0.05 0.02
Stochastic Oscillator 57.46 88.24

Price Performance

Historical Comparison
AGEN
HIX

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

About HIX Western Asset High Income Fund II Inc.

Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its primary investment objective is to maximize current income by investing at least 80% of its net assets, plus any borrowings for investment purposes, in high-yield debt securities. As a secondary objective, the Fund seeks capital appreciation to the extent consistent with its objective of seeking to maximize current income.

Share on Social Networks: